TY - JOUR
T1 - COVID-19-Associated Myocarditis
T2 - An Evolving Concern in Cardiology and Beyond
AU - Fraser, Meg
AU - Agdamag, Arianne Clare C.
AU - Maharaj, Valmiki R.
AU - Mutschler, Melinda
AU - Charpentier, Victoria
AU - Chowdhury, Mohammed
AU - Alexy, Tamas
N1 - Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/4
Y1 - 2022/4
N2 - The direct and indirect adverse effects of SARS-CoV-2 infection on the cardiovascular sys-tem, including myocarditis, are of paramount importance. These not only affect the disease course but also determine clinical outcomes and recovery. In this review, the authors aimed at providing an update on the incidence of Coronavirus disease-2019 (COVID-19)-associated myocarditis. Our knowledge and experience relevant to this area continues to evolve rapidly since the beginning of the pandemic. It is crucial for the scientific and medical community to stay abreast of current infor-mation. Contrasting early reports, recent data suggest that the overall incidence of SARS-CoV-2-associated myocarditis is relatively low, yet infected individuals are at a substantially increased risk. Therefore, understanding the pathophysiology and diagnostic evaluation, including the use of serum biomarkers and imaging modalities, remain important. This review aims to summarize the most recent data in these areas as they relate to COVID-19-associated myocarditis. Given its increasing relevance, a brief update is included on the proposed mechanisms of myocarditis in COVID-19 vaccine recipients.
AB - The direct and indirect adverse effects of SARS-CoV-2 infection on the cardiovascular sys-tem, including myocarditis, are of paramount importance. These not only affect the disease course but also determine clinical outcomes and recovery. In this review, the authors aimed at providing an update on the incidence of Coronavirus disease-2019 (COVID-19)-associated myocarditis. Our knowledge and experience relevant to this area continues to evolve rapidly since the beginning of the pandemic. It is crucial for the scientific and medical community to stay abreast of current infor-mation. Contrasting early reports, recent data suggest that the overall incidence of SARS-CoV-2-associated myocarditis is relatively low, yet infected individuals are at a substantially increased risk. Therefore, understanding the pathophysiology and diagnostic evaluation, including the use of serum biomarkers and imaging modalities, remain important. This review aims to summarize the most recent data in these areas as they relate to COVID-19-associated myocarditis. Given its increasing relevance, a brief update is included on the proposed mechanisms of myocarditis in COVID-19 vaccine recipients.
KW - COVID-19
KW - biomarkers
KW - cardiac imaging
KW - myocarditis
UR - http://www.scopus.com/inward/record.url?scp=85127980322&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127980322&partnerID=8YFLogxK
U2 - 10.3390/biology11040520
DO - 10.3390/biology11040520
M3 - Review article
C2 - 35453718
AN - SCOPUS:85127980322
VL - 11
JO - Biology
JF - Biology
IS - 4
M1 - 520
ER -
